• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Subsense Emerges from Stealth with $17M to Develop Non-Surgical Brain-Computer Interface

by Fred Pennic 02/18/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Subsense, Inc., a pioneering neurotechnology company announced its official launch and the closing of a $17 million seed funding round led by Golden Falcon Capital. 

– The company is developing a groundbreaking non-surgical, nanoparticle-based Brain-Computer Interface (BCI) with the potential to transform the treatment of neurological conditions.

Nanoparticle-Based Technology Aims to Enhance Treatment of Neurological Conditions

Subsense is co-founded by Tetiana Aleksandrova, a neurotechnology entrepreneur with a passion for developing innovative solutions for brain health and Artem Sokolov, a serial entrepreneur and early investor in successful companies like Asana, SoFi, and Coursera.Subsense’s innovative technology utilizes nanoparticles to establish a bidirectional connection between the brain and external devices. This approach allows for targeted neural stimulation and precise monitoring, opening up new possibilities for treating a wide range of neurological disorders.

“Brain-computer interfacing promises to unlock limitless human potential, but innovation has been held back by a lack of effective non-surgical approaches,” said Tetiana Aleksandrova, Subsense’s Chief Executive Officer. “By delivering nanoparticles that bind with receptors in the brain, Subsense can achieve more extensive connectivity with a far gentler approach.”

Collaborating with Leading Research Institutions

Subsense is collaborating with a consortium of leading neurological research institutions, including UC Santa Cruz and ETH Zurich, to accelerate the development and validation of its technology.

Targeting Neurological Conditions

Subsense’s initial focus is on developing therapies for neurological conditions such as:

  • Parkinson’s disease
  • Alzheimer’s disease
  • Epilepsy
  • Depression
  • Stroke
  • Chronic pain

Expanding the Possibilities of Brain-Computer Interfaces

Beyond therapeutic applications, Subsense is also exploring more expansive possibilities for its technology, including:

  • Sensorimotor recovery: Restoring vision, hearing, and movement.
  • Inner speech decoding: Translating thoughts into words.
  • AI integration: Merging the human brain with artificial neural networks.
  • External memory: Creating a backup and extension of human memory.
  • Mental health regulation: Monitoring and controlling emotions and mood.
  • Appetite control: Managing hunger and satiety signals.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

The Real Risk in Healthcare AI Isn’t the Model. It’s the Data. 

Clinical Data Fidelity: The Real Blindspot in Healthcare AI Strategy

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

M&A: Qualtrics Completes $6.75B Acquisition of Press Ganey Forsta

Viz.ai Launches Viz Pulmonary™ Suite: AI-Powered Workflows for COPD, Lung Nodules, and PE

Viz.ai Launches Viz Pulmonary™ Suite: AI-Powered Workflows for COPD, Lung Nodules, and PE

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |